

【4-9 メタアナリシス】

CQ		乳癌初期治療後患者において初期治療時の肥満が乳癌再発率を増加させるか？																																																																																																																																																															
P	乳癌初期治療後患者	I	初期治療時の肥満																																																																																																																																																														
C	診断時に非肥満の患者	O	乳癌再発リスク																																																																																																																																																														
研究デザイン	コホート研究	文献数	20	コード	Litton 2008, Sestak 2010, Ewertz 2012, Pajares 2013, Turkoz 2013, Jiralerspong 2013, Ligibel 2015, Scholz 2015, Widschwender 2015, Cecchini B-34 2016、Cecchini B-38 2016, Cecchini B-30, Gennari 2016, His 2016, Kawai 2016, Biganzoli 2017, Sun 2018、Vernaci 2019, Gondo 2020																																																																																																																																																												
モデル	コホート研究	方法	Inverse-variance method (RevMan5.3)																																																																																																																																																														
効果指標	リスク比	統合値	1.20 ( 1.12 - 1.29 ) P= <0.00001																																																																																																																																																														
Forest plot	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th rowspan="2">log[Hazard Ratio]</th> <th rowspan="2">SE</th> <th rowspan="2">Weight</th> <th colspan="2">Hazard Ratio</th> <th rowspan="2">Year</th> </tr> <tr> <th>IV, Random, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr><td>Litton 2008</td><td>-0.0202</td><td>0.1717</td><td>3.3%</td><td>0.98</td><td>[0.70, 1.37]</td><td>2008</td></tr> <tr><td>Sestak 2010</td><td>0.1655</td><td>0.0743</td><td>7.7%</td><td>1.18</td><td>[1.02, 1.36]</td><td>2010</td></tr> <tr><td>Ewertz 2012</td><td>0.0862</td><td>0.0756</td><td>7.7%</td><td>1.09</td><td>[0.94, 1.26]</td><td>2012</td></tr> <tr><td>Pajares 2013</td><td>0.2231</td><td>0.119</td><td>5.2%</td><td>1.25</td><td>[0.99, 1.58]</td><td>2013</td></tr> <tr><td>Pfeiler 2013</td><td>0.3716</td><td>0.1745</td><td>3.2%</td><td>1.45</td><td>[1.03, 2.04]</td><td>2013</td></tr> <tr><td>Turkoz 2013</td><td>0.4055</td><td>0.1582</td><td>3.7%</td><td>1.50</td><td>[1.10, 2.05]</td><td>2013</td></tr> <tr><td>Jiralerspong 2013</td><td>0.1655</td><td>0.0743</td><td>7.7%</td><td>1.18</td><td>[1.02, 1.36]</td><td>2013</td></tr> <tr><td>Ligibel 2015</td><td>0.077</td><td>0.0292</td><td>10.6%</td><td>1.08</td><td>[1.02, 1.14]</td><td>2015</td></tr> <tr><td>Scholz 2015</td><td>0.3577</td><td>0.1292</td><td>4.7%</td><td>1.43</td><td>[1.11, 1.84]</td><td>2015</td></tr> <tr><td>Widschwender 2015</td><td>0.9933</td><td>0.233</td><td>2.0%</td><td>2.70</td><td>[1.71, 4.26]</td><td>2015</td></tr> <tr><td>Cecchini B-34 2016</td><td>0</td><td>0.14</td><td>4.3%</td><td>1.00</td><td>[0.76, 1.32]</td><td>2016</td></tr> <tr><td>Cecchini B-38 2016</td><td>0.1222</td><td>0.0939</td><td>6.5%</td><td>1.13</td><td>[0.94, 1.36]</td><td>2016</td></tr> <tr><td>Gennari 2016</td><td>0.0953</td><td>0.182</td><td>3.0%</td><td>1.10</td><td>[0.77, 1.57]</td><td>2016</td></tr> <tr><td>His 2016</td><td>-0.0305</td><td>0.1888</td><td>2.8%</td><td>0.97</td><td>[0.67, 1.40]</td><td>2016</td></tr> <tr><td>Kawai 2016</td><td>0.1398</td><td>0.0975</td><td>6.3%</td><td>1.15</td><td>[0.95, 1.39]</td><td>2016</td></tr> <tr><td>Cecchini B-30 2016</td><td>0.157</td><td>0.07</td><td>8.0%</td><td>1.17</td><td>[1.02, 1.34]</td><td>2016</td></tr> <tr><td>Biganzoli 2017</td><td>-0.0408</td><td>0.1059</td><td>5.8%</td><td>0.96</td><td>[0.78, 1.18]</td><td>2017</td></tr> <tr><td>Sun 2018</td><td>0.6355</td><td>0.1979</td><td>2.6%</td><td>1.89</td><td>[1.28, 2.78]</td><td>2018</td></tr> <tr><td>Vernaci 2019</td><td>0.3988</td><td>0.1835</td><td>3.0%</td><td>1.49</td><td>[1.04, 2.13]</td><td>2019</td></tr> <tr><td>Gondo 2020</td><td>0.6043</td><td>0.2551</td><td>1.8%</td><td>1.83</td><td>[1.11, 3.02]</td><td>2020</td></tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.20</b></td> <td><b>[1.12, 1.29]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Tau<sup>2</sup> = 0.01; Chi<sup>2</sup> = 43.76, df = 19 (P = 0.001); I<sup>2</sup> = 57%  Test for overall effect: Z = 4.99 (P &lt; 0.00001)</p>				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio		Year	IV, Random, 95% CI	Year	Litton 2008	-0.0202	0.1717	3.3%	0.98	[0.70, 1.37]	2008	Sestak 2010	0.1655	0.0743	7.7%	1.18	[1.02, 1.36]	2010	Ewertz 2012	0.0862	0.0756	7.7%	1.09	[0.94, 1.26]	2012	Pajares 2013	0.2231	0.119	5.2%	1.25	[0.99, 1.58]	2013	Pfeiler 2013	0.3716	0.1745	3.2%	1.45	[1.03, 2.04]	2013	Turkoz 2013	0.4055	0.1582	3.7%	1.50	[1.10, 2.05]	2013	Jiralerspong 2013	0.1655	0.0743	7.7%	1.18	[1.02, 1.36]	2013	Ligibel 2015	0.077	0.0292	10.6%	1.08	[1.02, 1.14]	2015	Scholz 2015	0.3577	0.1292	4.7%	1.43	[1.11, 1.84]	2015	Widschwender 2015	0.9933	0.233	2.0%	2.70	[1.71, 4.26]	2015	Cecchini B-34 2016	0	0.14	4.3%	1.00	[0.76, 1.32]	2016	Cecchini B-38 2016	0.1222	0.0939	6.5%	1.13	[0.94, 1.36]	2016	Gennari 2016	0.0953	0.182	3.0%	1.10	[0.77, 1.57]	2016	His 2016	-0.0305	0.1888	2.8%	0.97	[0.67, 1.40]	2016	Kawai 2016	0.1398	0.0975	6.3%	1.15	[0.95, 1.39]	2016	Cecchini B-30 2016	0.157	0.07	8.0%	1.17	[1.02, 1.34]	2016	Biganzoli 2017	-0.0408	0.1059	5.8%	0.96	[0.78, 1.18]	2017	Sun 2018	0.6355	0.1979	2.6%	1.89	[1.28, 2.78]	2018	Vernaci 2019	0.3988	0.1835	3.0%	1.49	[1.04, 2.13]	2019	Gondo 2020	0.6043	0.2551	1.8%	1.83	[1.11, 3.02]	2020	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.20</b>	<b>[1.12, 1.29]</b>		<p>コメント： 異質性はあるが、全体としては有意</p>
Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio					Year																																																																																																																																																								
				IV, Random, 95% CI	Year																																																																																																																																																												
Litton 2008	-0.0202	0.1717	3.3%	0.98	[0.70, 1.37]	2008																																																																																																																																																											
Sestak 2010	0.1655	0.0743	7.7%	1.18	[1.02, 1.36]	2010																																																																																																																																																											
Ewertz 2012	0.0862	0.0756	7.7%	1.09	[0.94, 1.26]	2012																																																																																																																																																											
Pajares 2013	0.2231	0.119	5.2%	1.25	[0.99, 1.58]	2013																																																																																																																																																											
Pfeiler 2013	0.3716	0.1745	3.2%	1.45	[1.03, 2.04]	2013																																																																																																																																																											
Turkoz 2013	0.4055	0.1582	3.7%	1.50	[1.10, 2.05]	2013																																																																																																																																																											
Jiralerspong 2013	0.1655	0.0743	7.7%	1.18	[1.02, 1.36]	2013																																																																																																																																																											
Ligibel 2015	0.077	0.0292	10.6%	1.08	[1.02, 1.14]	2015																																																																																																																																																											
Scholz 2015	0.3577	0.1292	4.7%	1.43	[1.11, 1.84]	2015																																																																																																																																																											
Widschwender 2015	0.9933	0.233	2.0%	2.70	[1.71, 4.26]	2015																																																																																																																																																											
Cecchini B-34 2016	0	0.14	4.3%	1.00	[0.76, 1.32]	2016																																																																																																																																																											
Cecchini B-38 2016	0.1222	0.0939	6.5%	1.13	[0.94, 1.36]	2016																																																																																																																																																											
Gennari 2016	0.0953	0.182	3.0%	1.10	[0.77, 1.57]	2016																																																																																																																																																											
His 2016	-0.0305	0.1888	2.8%	0.97	[0.67, 1.40]	2016																																																																																																																																																											
Kawai 2016	0.1398	0.0975	6.3%	1.15	[0.95, 1.39]	2016																																																																																																																																																											
Cecchini B-30 2016	0.157	0.07	8.0%	1.17	[1.02, 1.34]	2016																																																																																																																																																											
Biganzoli 2017	-0.0408	0.1059	5.8%	0.96	[0.78, 1.18]	2017																																																																																																																																																											
Sun 2018	0.6355	0.1979	2.6%	1.89	[1.28, 2.78]	2018																																																																																																																																																											
Vernaci 2019	0.3988	0.1835	3.0%	1.49	[1.04, 2.13]	2019																																																																																																																																																											
Gondo 2020	0.6043	0.2551	1.8%	1.83	[1.11, 3.02]	2020																																																																																																																																																											
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.20</b>	<b>[1.12, 1.29]</b>																																																																																																																																																												
Funnel plot	<p>コメント： 報告バイアスを示唆する分布は認められない。</p>																																																																																																																																																																
その他の解析	施行せず。			コメント：																																																																																																																																																													
メタリグレーション																																																																																																																																																																	
感度分析																																																																																																																																																																	

【4-9 メタアナリシス】

CQ		乳癌初期治療後患者において初期治療時の肥満が乳癌死亡率を増加させるか？																																																																																																																					
P	乳癌初期治療後患者	I	初期治療時の肥満																																																																																																																				
C	診断時に非肥満の患者	O	乳癌死亡リスク																																																																																																																				
研究デザイン	コホート研究	文献数	17	コード	Sestak 2010, Maskarinec 2011, Jiralerspong 2013, Pajares 2013, Turkoz 2013, Jeon 2015, Sun 2015, Taghizadeh 2015, His 2016, Kawai 2016, McCullough 2016, Nelson 2016, Elwood 2018, Sun 2018, Nur 2019, Oudanoh 2019, Gondo 2020																																																																																																																		
モデル	コホート研究	方法	Inverse-variance method (RevMan5.3)																																																																																																																				
効果指標	リスク比	統合値	1.31 ( 1.21 - 1.42 ) P= <0.0001																																																																																																																				
Forest plot	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr><td>Sestak 2010</td><td>0.4383</td><td>0.175</td><td>5.4%</td><td>1.55 [1.10, 2.18]</td><td>2010</td></tr> <tr><td>Maskarinec 2011</td><td>1.0953</td><td>0.4574</td><td>0.8%</td><td>2.99 [1.22, 7.33]</td><td>2011</td></tr> <tr><td>Jiralerspong 2013</td><td>0.1906</td><td>0.1076</td><td>14.3%</td><td>1.21 [0.98, 1.49]</td><td>2013</td></tr> <tr><td>Pajares 2013</td><td>0.2776</td><td>0.1417</td><td>8.2%</td><td>1.32 [1.00, 1.74]</td><td>2013</td></tr> <tr><td>Turkoz 2013</td><td>0.5878</td><td>0.2069</td><td>3.9%</td><td>1.80 [1.20, 2.70]</td><td>2013</td></tr> <tr><td>Jeon 2015</td><td>0.1906</td><td>0.0872</td><td>21.7%</td><td>1.21 [1.02, 1.44]</td><td>2015</td></tr> <tr><td>Sun 2015</td><td>0.01</td><td>0.1798</td><td>5.1%</td><td>1.01 [0.71, 1.44]</td><td>2015</td></tr> <tr><td>Taghizadeh 2015</td><td>0.4187</td><td>0.2789</td><td>2.1%</td><td>1.52 [0.88, 2.63]</td><td>2015</td></tr> <tr><td>Nelson 2016</td><td>0.0488</td><td>0.12</td><td>11.5%</td><td>1.05 [0.83, 1.33]</td><td>2016</td></tr> <tr><td>His 2016</td><td>0.3365</td><td>0.305</td><td>1.8%</td><td>1.40 [0.77, 2.55]</td><td>2016</td></tr> <tr><td>Kawai 2016</td><td>0.3853</td><td>0.1433</td><td>8.0%</td><td>1.47 [1.11, 1.95]</td><td>2016</td></tr> <tr><td>McCullough 2016</td><td>0.4886</td><td>0.178</td><td>5.2%</td><td>1.63 [1.15, 2.31]</td><td>2016</td></tr> <tr><td>Elwood 2018</td><td>-0.0408</td><td>0.275</td><td>2.2%</td><td>0.96 [0.56, 1.65]</td><td>2018</td></tr> <tr><td>Sun 2018</td><td>0.7188</td><td>0.248</td><td>2.7%</td><td>2.05 [1.26, 3.34]</td><td>2018</td></tr> <tr><td>Nur 2019</td><td>0.3716</td><td>0.2971</td><td>1.9%</td><td>1.45 [0.81, 2.60]</td><td>2019</td></tr> <tr><td>Oudanoh 2019</td><td>0.2852</td><td>0.1936</td><td>4.4%</td><td>1.33 [0.91, 1.94]</td><td>2019</td></tr> <tr><td>Gondo 2020</td><td>1.0043</td><td>0.4411</td><td>0.8%</td><td>2.73 [1.15, 6.48]</td><td>2020</td></tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.31 [1.21, 1.42]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 23.34, df = 16 (P = 0.10); I<sup>2</sup> = 31%  Test for overall effect: Z = 6.65 (P &lt; 0.00001)</p>				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year	Sestak 2010	0.4383	0.175	5.4%	1.55 [1.10, 2.18]	2010	Maskarinec 2011	1.0953	0.4574	0.8%	2.99 [1.22, 7.33]	2011	Jiralerspong 2013	0.1906	0.1076	14.3%	1.21 [0.98, 1.49]	2013	Pajares 2013	0.2776	0.1417	8.2%	1.32 [1.00, 1.74]	2013	Turkoz 2013	0.5878	0.2069	3.9%	1.80 [1.20, 2.70]	2013	Jeon 2015	0.1906	0.0872	21.7%	1.21 [1.02, 1.44]	2015	Sun 2015	0.01	0.1798	5.1%	1.01 [0.71, 1.44]	2015	Taghizadeh 2015	0.4187	0.2789	2.1%	1.52 [0.88, 2.63]	2015	Nelson 2016	0.0488	0.12	11.5%	1.05 [0.83, 1.33]	2016	His 2016	0.3365	0.305	1.8%	1.40 [0.77, 2.55]	2016	Kawai 2016	0.3853	0.1433	8.0%	1.47 [1.11, 1.95]	2016	McCullough 2016	0.4886	0.178	5.2%	1.63 [1.15, 2.31]	2016	Elwood 2018	-0.0408	0.275	2.2%	0.96 [0.56, 1.65]	2018	Sun 2018	0.7188	0.248	2.7%	2.05 [1.26, 3.34]	2018	Nur 2019	0.3716	0.2971	1.9%	1.45 [0.81, 2.60]	2019	Oudanoh 2019	0.2852	0.1936	4.4%	1.33 [0.91, 1.94]	2019	Gondo 2020	1.0043	0.4411	0.8%	2.73 [1.15, 6.48]	2020	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.31 [1.21, 1.42]</b>		コメント: 異質性は低く、有意である。
Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year																																																																																																																		
Sestak 2010	0.4383	0.175	5.4%	1.55 [1.10, 2.18]	2010																																																																																																																		
Maskarinec 2011	1.0953	0.4574	0.8%	2.99 [1.22, 7.33]	2011																																																																																																																		
Jiralerspong 2013	0.1906	0.1076	14.3%	1.21 [0.98, 1.49]	2013																																																																																																																		
Pajares 2013	0.2776	0.1417	8.2%	1.32 [1.00, 1.74]	2013																																																																																																																		
Turkoz 2013	0.5878	0.2069	3.9%	1.80 [1.20, 2.70]	2013																																																																																																																		
Jeon 2015	0.1906	0.0872	21.7%	1.21 [1.02, 1.44]	2015																																																																																																																		
Sun 2015	0.01	0.1798	5.1%	1.01 [0.71, 1.44]	2015																																																																																																																		
Taghizadeh 2015	0.4187	0.2789	2.1%	1.52 [0.88, 2.63]	2015																																																																																																																		
Nelson 2016	0.0488	0.12	11.5%	1.05 [0.83, 1.33]	2016																																																																																																																		
His 2016	0.3365	0.305	1.8%	1.40 [0.77, 2.55]	2016																																																																																																																		
Kawai 2016	0.3853	0.1433	8.0%	1.47 [1.11, 1.95]	2016																																																																																																																		
McCullough 2016	0.4886	0.178	5.2%	1.63 [1.15, 2.31]	2016																																																																																																																		
Elwood 2018	-0.0408	0.275	2.2%	0.96 [0.56, 1.65]	2018																																																																																																																		
Sun 2018	0.7188	0.248	2.7%	2.05 [1.26, 3.34]	2018																																																																																																																		
Nur 2019	0.3716	0.2971	1.9%	1.45 [0.81, 2.60]	2019																																																																																																																		
Oudanoh 2019	0.2852	0.1936	4.4%	1.33 [0.91, 1.94]	2019																																																																																																																		
Gondo 2020	1.0043	0.4411	0.8%	2.73 [1.15, 6.48]	2020																																																																																																																		
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.31 [1.21, 1.42]</b>																																																																																																																			
Funnel plot					コメント: 報告バイアスを示唆する分布を認めた。																																																																																																																		
その他の解析	施行せず。			コメント:																																																																																																																			
メタリグレッション																																																																																																																							
感度分析																																																																																																																							

【4-9 メタアナリシス】

CQ		乳癌初期治療後患者において初期治療時の肥満が全死亡率を増加させるか？																																																																																																																																																															
P	乳癌初期治療後患者	I	初期治療時の肥満																																																																																																																																																														
C	診断時に非肥満の患者	O	全死亡リスク																																																																																																																																																														
研究デザイン	コホート研究	文献数	24	コード	Xing P 2013, Jiralerspong S 2013, Pfeiler G 2011, Ewertz M 2012, Gnani M 2013, Litton JK 2008, Ladoire S 2014, Gennari A 2016, Cecchini RS B-30 2016, Cecchini RS B-31 2016, Cecchini RS B-34 2016, Cecchini RS B-38 2016, Widschwendter P 2015, Ligibel JA																																																																																																																																																												
モデル	コホート研究	方法	Inverse-variance method (RevMan5.3)																																																																																																																																																														
効果指標	リスク比	統合値	1.30 ( 1.21 - 1.41 ) P= <0.0001																																																																																																																																																														
Forest plot	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Random, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr><td>Litton 2008</td><td>0.5008</td><td>0.1711</td><td>3.2%</td><td>1.65 [1.18, 2.31]</td><td>2008</td></tr> <tr><td>Maskarinec 2011</td><td>0.7227</td><td>0.2631</td><td>1.7%</td><td>2.06 [1.23, 3.45]</td><td>2011</td></tr> <tr><td>Ewertz 2012</td><td>0.174</td><td>0.0939</td><td>5.7%</td><td>1.19 [0.99, 1.43]</td><td>2012</td></tr> <tr><td>Pfeiler 2013</td><td>0.5933</td><td>0.2449</td><td>1.9%</td><td>1.81 [1.12, 2.93]</td><td>2013</td></tr> <tr><td>Jiralerspong 2013</td><td>0.1823</td><td>0.093</td><td>5.8%</td><td>1.20 [1.00, 1.44]</td><td>2013</td></tr> <tr><td>Pajares 2013</td><td>0.3001</td><td>0.1234</td><td>4.6%</td><td>1.35 [1.06, 1.72]</td><td>2013</td></tr> <tr><td>Jeon 2015</td><td>0.2546</td><td>0.0676</td><td>6.8%</td><td>1.29 [1.13, 1.47]</td><td>2015</td></tr> <tr><td>Ligibel 2015</td><td>0.077</td><td>0.0342</td><td>8.0%</td><td>1.08 [1.01, 1.15]</td><td>2015</td></tr> <tr><td>Scholz 2015</td><td>0.4447</td><td>0.16</td><td>3.5%</td><td>1.56 [1.14, 2.13]</td><td>2015</td></tr> <tr><td>Sun 2015</td><td>0.0677</td><td>0.142</td><td>4.0%</td><td>1.07 [0.81, 1.41]</td><td>2015</td></tr> <tr><td>Widschwendter 2015</td><td>1.026</td><td>0.2742</td><td>1.6%</td><td>2.79 [1.63, 4.78]</td><td>2015</td></tr> <tr><td>His 2016</td><td>0</td><td>0.2606</td><td>1.8%</td><td>1.00 [0.60, 1.67]</td><td>2016</td></tr> <tr><td>Kawai 2016</td><td>0.3784</td><td>0.1174</td><td>4.8%</td><td>1.46 [1.16, 1.84]</td><td>2016</td></tr> <tr><td>McCullough 2016</td><td>0.3075</td><td>0.1176</td><td>4.8%</td><td>1.36 [1.08, 1.71]</td><td>2016</td></tr> <tr><td>Nelson 2016</td><td>0.27</td><td>0.0799</td><td>6.3%</td><td>1.31 [1.12, 1.53]</td><td>2016</td></tr> <tr><td>Cecchini B-30 2016</td><td>0.1655</td><td>0.0743</td><td>6.5%</td><td>1.18 [1.02, 1.36]</td><td>2016</td></tr> <tr><td>Cecchini B-34 2016</td><td>0.0296</td><td>0.0688</td><td>6.8%</td><td>1.03 [0.90, 1.18]</td><td>2016</td></tr> <tr><td>Cecchini B-38 2016</td><td>0.1044</td><td>0.0958</td><td>5.6%</td><td>1.11 [0.92, 1.34]</td><td>2016</td></tr> <tr><td>Gennari 2016</td><td>0.1133</td><td>0.2398</td><td>2.0%</td><td>1.12 [0.70, 1.79]</td><td>2016</td></tr> <tr><td>Elwood 2018</td><td>0.0296</td><td>0.2508</td><td>1.9%</td><td>1.03 [0.63, 1.68]</td><td>2018</td></tr> <tr><td>Nur 2019</td><td>0.4886</td><td>0.1915</td><td>2.8%</td><td>1.63 [1.12, 2.37]</td><td>2019</td></tr> <tr><td>Oudanonh 2019</td><td>0.392</td><td>0.1377</td><td>4.1%</td><td>1.48 [1.13, 1.94]</td><td>2019</td></tr> <tr><td>Vernaci 2019</td><td>0.4447</td><td>0.1381</td><td>4.1%</td><td>1.56 [1.19, 2.04]</td><td>2019</td></tr> <tr><td>Gondo 2020</td><td>0.8879</td><td>0.2887</td><td>1.5%</td><td>2.43 [1.38, 4.28]</td><td>2020</td></tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.30 [1.21, 1.41]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Tau<sup>2</sup> = 0.02; Chi<sup>2</sup> = 61.02, df = 23 (P &lt; 0.0001); I<sup>2</sup> = 62%  Test for overall effect: Z = 6.84 (P &lt; 0.00001)</p>				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI	Year	Litton 2008	0.5008	0.1711	3.2%	1.65 [1.18, 2.31]	2008	Maskarinec 2011	0.7227	0.2631	1.7%	2.06 [1.23, 3.45]	2011	Ewertz 2012	0.174	0.0939	5.7%	1.19 [0.99, 1.43]	2012	Pfeiler 2013	0.5933	0.2449	1.9%	1.81 [1.12, 2.93]	2013	Jiralerspong 2013	0.1823	0.093	5.8%	1.20 [1.00, 1.44]	2013	Pajares 2013	0.3001	0.1234	4.6%	1.35 [1.06, 1.72]	2013	Jeon 2015	0.2546	0.0676	6.8%	1.29 [1.13, 1.47]	2015	Ligibel 2015	0.077	0.0342	8.0%	1.08 [1.01, 1.15]	2015	Scholz 2015	0.4447	0.16	3.5%	1.56 [1.14, 2.13]	2015	Sun 2015	0.0677	0.142	4.0%	1.07 [0.81, 1.41]	2015	Widschwendter 2015	1.026	0.2742	1.6%	2.79 [1.63, 4.78]	2015	His 2016	0	0.2606	1.8%	1.00 [0.60, 1.67]	2016	Kawai 2016	0.3784	0.1174	4.8%	1.46 [1.16, 1.84]	2016	McCullough 2016	0.3075	0.1176	4.8%	1.36 [1.08, 1.71]	2016	Nelson 2016	0.27	0.0799	6.3%	1.31 [1.12, 1.53]	2016	Cecchini B-30 2016	0.1655	0.0743	6.5%	1.18 [1.02, 1.36]	2016	Cecchini B-34 2016	0.0296	0.0688	6.8%	1.03 [0.90, 1.18]	2016	Cecchini B-38 2016	0.1044	0.0958	5.6%	1.11 [0.92, 1.34]	2016	Gennari 2016	0.1133	0.2398	2.0%	1.12 [0.70, 1.79]	2016	Elwood 2018	0.0296	0.2508	1.9%	1.03 [0.63, 1.68]	2018	Nur 2019	0.4886	0.1915	2.8%	1.63 [1.12, 2.37]	2019	Oudanonh 2019	0.392	0.1377	4.1%	1.48 [1.13, 1.94]	2019	Vernaci 2019	0.4447	0.1381	4.1%	1.56 [1.19, 2.04]	2019	Gondo 2020	0.8879	0.2887	1.5%	2.43 [1.38, 4.28]	2020	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.30 [1.21, 1.41]</b>		コメント: 異質性はあるが、全体としては有意
Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI	Year																																																																																																																																																												
Litton 2008	0.5008	0.1711	3.2%	1.65 [1.18, 2.31]	2008																																																																																																																																																												
Maskarinec 2011	0.7227	0.2631	1.7%	2.06 [1.23, 3.45]	2011																																																																																																																																																												
Ewertz 2012	0.174	0.0939	5.7%	1.19 [0.99, 1.43]	2012																																																																																																																																																												
Pfeiler 2013	0.5933	0.2449	1.9%	1.81 [1.12, 2.93]	2013																																																																																																																																																												
Jiralerspong 2013	0.1823	0.093	5.8%	1.20 [1.00, 1.44]	2013																																																																																																																																																												
Pajares 2013	0.3001	0.1234	4.6%	1.35 [1.06, 1.72]	2013																																																																																																																																																												
Jeon 2015	0.2546	0.0676	6.8%	1.29 [1.13, 1.47]	2015																																																																																																																																																												
Ligibel 2015	0.077	0.0342	8.0%	1.08 [1.01, 1.15]	2015																																																																																																																																																												
Scholz 2015	0.4447	0.16	3.5%	1.56 [1.14, 2.13]	2015																																																																																																																																																												
Sun 2015	0.0677	0.142	4.0%	1.07 [0.81, 1.41]	2015																																																																																																																																																												
Widschwendter 2015	1.026	0.2742	1.6%	2.79 [1.63, 4.78]	2015																																																																																																																																																												
His 2016	0	0.2606	1.8%	1.00 [0.60, 1.67]	2016																																																																																																																																																												
Kawai 2016	0.3784	0.1174	4.8%	1.46 [1.16, 1.84]	2016																																																																																																																																																												
McCullough 2016	0.3075	0.1176	4.8%	1.36 [1.08, 1.71]	2016																																																																																																																																																												
Nelson 2016	0.27	0.0799	6.3%	1.31 [1.12, 1.53]	2016																																																																																																																																																												
Cecchini B-30 2016	0.1655	0.0743	6.5%	1.18 [1.02, 1.36]	2016																																																																																																																																																												
Cecchini B-34 2016	0.0296	0.0688	6.8%	1.03 [0.90, 1.18]	2016																																																																																																																																																												
Cecchini B-38 2016	0.1044	0.0958	5.6%	1.11 [0.92, 1.34]	2016																																																																																																																																																												
Gennari 2016	0.1133	0.2398	2.0%	1.12 [0.70, 1.79]	2016																																																																																																																																																												
Elwood 2018	0.0296	0.2508	1.9%	1.03 [0.63, 1.68]	2018																																																																																																																																																												
Nur 2019	0.4886	0.1915	2.8%	1.63 [1.12, 2.37]	2019																																																																																																																																																												
Oudanonh 2019	0.392	0.1377	4.1%	1.48 [1.13, 1.94]	2019																																																																																																																																																												
Vernaci 2019	0.4447	0.1381	4.1%	1.56 [1.19, 2.04]	2019																																																																																																																																																												
Gondo 2020	0.8879	0.2887	1.5%	2.43 [1.38, 4.28]	2020																																																																																																																																																												
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.30 [1.21, 1.41]</b>																																																																																																																																																													
Funnel plot					コメント: 報告バイアスを示唆する分布は認められない。																																																																																																																																																												
その他の解析	施行せず。			コメント:																																																																																																																																																													
メタリグレーション																																																																																																																																																																	
感度分析																																																																																																																																																																	

【4-9 メタアナリシス】

<b>CQ</b>		HR+HER2-乳癌初期治療後患者において初期治療時の肥満が乳癌再発率を増加させるか？																																													
<b>P</b>	HR+HER2-乳癌初期治療後患者	<b>I</b>	初期治療時の肥満																																												
<b>C</b>	診断時に非肥満の患者	<b>O</b>	乳癌再発リスク																																												
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	5	<b>コード</b>	Sparano E1199 2012, Robinson 2014, Widschwender 2015, Kawai 2016,																																										
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																												
<b>効果指標</b>	リスク比	<b>統合値</b>	1.27 ( 1.12 - 1.45 ) P= 0.0002																																												
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>Sparano E1199 2012</td> <td>0.2151</td> <td>0.08</td> <td>67.6%</td> <td>1.24 [1.06, 1.45]</td> <td>2012</td> </tr> <tr> <td>Robinson 2014</td> <td>0.5365</td> <td>0.2159</td> <td>9.3%</td> <td>1.71 [1.12, 2.61]</td> <td>2014</td> </tr> <tr> <td>Widschwender 2015</td> <td>1.2</td> <td>0.5321</td> <td>1.5%</td> <td>3.32 [1.17, 9.42]</td> <td>2015</td> </tr> <tr> <td>Kawai 2016</td> <td>0.207</td> <td>0.1594</td> <td>17.0%</td> <td>1.23 [0.90, 1.68]</td> <td>2016</td> </tr> <tr> <td>Abubaker 2018</td> <td>-0.1508</td> <td>0.3083</td> <td>4.6%</td> <td>0.86 [0.47, 1.57]</td> <td>2018</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.27 [1.12, 1.45]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 6.89, df = 4 (P = 0.14); I<sup>2</sup> = 42%            Test for overall effect: Z = 3.68 (P = 0.0002)</p>					Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year	Sparano E1199 2012	0.2151	0.08	67.6%	1.24 [1.06, 1.45]	2012	Robinson 2014	0.5365	0.2159	9.3%	1.71 [1.12, 2.61]	2014	Widschwender 2015	1.2	0.5321	1.5%	3.32 [1.17, 9.42]	2015	Kawai 2016	0.207	0.1594	17.0%	1.23 [0.90, 1.68]	2016	Abubaker 2018	-0.1508	0.3083	4.6%	0.86 [0.47, 1.57]	2018	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.27 [1.12, 1.45]</b>	
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year																																									
Sparano E1199 2012	0.2151	0.08	67.6%	1.24 [1.06, 1.45]	2012																																										
Robinson 2014	0.5365	0.2159	9.3%	1.71 [1.12, 2.61]	2014																																										
Widschwender 2015	1.2	0.5321	1.5%	3.32 [1.17, 9.42]	2015																																										
Kawai 2016	0.207	0.1594	17.0%	1.23 [0.90, 1.68]	2016																																										
Abubaker 2018	-0.1508	0.3083	4.6%	0.86 [0.47, 1.57]	2018																																										
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.27 [1.12, 1.45]</b>																																											
<p>コメント： 異質性は中等度であり、効果は有意である。</p>																																															
<b>Funnel plot</b>																																															
	<p>コメント： 報告バイアスを示唆する分布を認めた。</p>																																														
<b>その他の解析</b>	施行せず。				コメント：																																										
メタリグレーション																																															
感度分析																																															

【4-9 メタアナリシス】

<b>CQ</b>		HR+HER2-乳癌初期治療後患者において初期治療時の肥満が乳癌再発率を増加させるか？																																							
<b>P</b>	HR+HER2-乳癌初期治療後患者	<b>I</b>	初期治療時の肥満																																						
<b>C</b>	診断時に非肥満の患者	<b>O</b>	乳癌死亡リスク																																						
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	4	<b>コード</b>	Sparano E1199 2012, Sun 2015, Jeon 2015, Kawai 2016																																				
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																						
<b>効果指標</b>	リスク比	<b>統合値</b>	1.31 ( 1.17 - 1.48 ) P= <0.00001																																						
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>Sparano E1199 2012</td> <td>0.3365</td> <td>0.1184</td> <td>25.9%</td> <td>1.40 [1.11, 1.77]</td> <td>2012</td> </tr> <tr> <td>Sun 2015</td> <td>-0.1508</td> <td>0.247</td> <td>5.9%</td> <td>0.86 [0.53, 1.40]</td> <td>2015</td> </tr> <tr> <td>Jeon 2015</td> <td>0.27</td> <td>0.0754</td> <td>63.8%</td> <td>1.31 [1.13, 1.52]</td> <td>2015</td> </tr> <tr> <td>Kawai 2016</td> <td>0.4947</td> <td>0.2894</td> <td>4.3%</td> <td>1.64 [0.93, 2.89]</td> <td>2016</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.31 [1.17, 1.48]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 3.82, df = 3 (P = 0.28); I<sup>2</sup> = 21% Test for overall effect: Z = 4.51 (P &lt; 0.00001)</p>					Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year	Sparano E1199 2012	0.3365	0.1184	25.9%	1.40 [1.11, 1.77]	2012	Sun 2015	-0.1508	0.247	5.9%	0.86 [0.53, 1.40]	2015	Jeon 2015	0.27	0.0754	63.8%	1.31 [1.13, 1.52]	2015	Kawai 2016	0.4947	0.2894	4.3%	1.64 [0.93, 2.89]	2016	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.31 [1.17, 1.48]</b>	
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year																																			
Sparano E1199 2012	0.3365	0.1184	25.9%	1.40 [1.11, 1.77]	2012																																				
Sun 2015	-0.1508	0.247	5.9%	0.86 [0.53, 1.40]	2015																																				
Jeon 2015	0.27	0.0754	63.8%	1.31 [1.13, 1.52]	2015																																				
Kawai 2016	0.4947	0.2894	4.3%	1.64 [0.93, 2.89]	2016																																				
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.31 [1.17, 1.48]</b>																																					
	<p>コメント： 異質性は低く、効果は有意である。</p>																																								
<b>Funnel plot</b>	<p>コメント： 報告バイアスを示唆する分布は認められない。</p>																																								
	<p>コメント： 施行せず。</p>																																								
<b>その他の解析</b>	<p>施行せず。</p>				コメント：																																				
メタリグレーション																																									
感度分析																																									

【4-9 メタアナリシス】

<b>CQ</b>		HR+HER2-乳癌初期治療後患者において初期治療時の肥満が乳癌再発率を増加させるか？																																																			
<b>P</b>	HR+HER2-乳癌初期治療後患者	<b>I</b>	初期治療時の肥満																																																		
<b>C</b>	診断時に非肥満の患者	<b>O</b>	全死亡リスク																																																		
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	6	<b>コード</b>	Sparano E1199 2012, Turkoz 2013, Jeon 2015, Sun 2015, Widschwender 2015,																																																
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																																		
<b>効果指標</b>	リスク比	<b>統合値</b>	1.32 ( 1.16 - 1.49 ) P= <0.0001																																																		
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>Sparano E1199 2012</td> <td>0.3148</td> <td>0.0983</td> <td>41.5%</td> <td>1.37 [1.13, 1.66]</td> <td>2012</td> </tr> <tr> <td>Turkoz 2013</td> <td>0.4055</td> <td>0.2069</td> <td>9.4%</td> <td>1.50 [1.00, 2.25]</td> <td>2013</td> </tr> <tr> <td>Jeon 2015</td> <td>0.392</td> <td>0.1156</td> <td>30.0%</td> <td>1.48 [1.18, 1.86]</td> <td>2015</td> </tr> <tr> <td>Sun 2015</td> <td>-0.0943</td> <td>0.1876</td> <td>11.4%</td> <td>0.91 [0.63, 1.31]</td> <td>2015</td> </tr> <tr> <td>Widschwender 2015</td> <td>1.0438</td> <td>0.7073</td> <td>0.8%</td> <td>2.84 [0.71, 11.36]</td> <td>2015</td> </tr> <tr> <td>Abubaker 2018</td> <td>-0.1278</td> <td>0.2398</td> <td>7.0%</td> <td>0.88 [0.55, 1.41]</td> <td>2018</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.32 [1.16, 1.49]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 9.46, df = 5 (P = 0.09); I<sup>2</sup> = 47% Test for overall effect: Z = 4.34 (P &lt; 0.0001)</p>					Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year	Sparano E1199 2012	0.3148	0.0983	41.5%	1.37 [1.13, 1.66]	2012	Turkoz 2013	0.4055	0.2069	9.4%	1.50 [1.00, 2.25]	2013	Jeon 2015	0.392	0.1156	30.0%	1.48 [1.18, 1.86]	2015	Sun 2015	-0.0943	0.1876	11.4%	0.91 [0.63, 1.31]	2015	Widschwender 2015	1.0438	0.7073	0.8%	2.84 [0.71, 11.36]	2015	Abubaker 2018	-0.1278	0.2398	7.0%	0.88 [0.55, 1.41]	2018	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.32 [1.16, 1.49]</b>	
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year																																															
Sparano E1199 2012	0.3148	0.0983	41.5%	1.37 [1.13, 1.66]	2012																																																
Turkoz 2013	0.4055	0.2069	9.4%	1.50 [1.00, 2.25]	2013																																																
Jeon 2015	0.392	0.1156	30.0%	1.48 [1.18, 1.86]	2015																																																
Sun 2015	-0.0943	0.1876	11.4%	0.91 [0.63, 1.31]	2015																																																
Widschwender 2015	1.0438	0.7073	0.8%	2.84 [0.71, 11.36]	2015																																																
Abubaker 2018	-0.1278	0.2398	7.0%	0.88 [0.55, 1.41]	2018																																																
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.32 [1.16, 1.49]</b>																																																	
<p>コメント: 異質性は中等度であり、効果は有意である。</p>																																																					
<b>Funnel plot</b>																																																					
	<p>コメント: 報告バイアスを示唆する分布は認められない。</p>																																																				
<b>その他の解析</b>	施行せず。				コメント:																																																
メタリグレーション																																																					
感度分析																																																					

【4-9 メタアナリシス】

<b>CQ</b>		HER2+乳癌初期治療後患者において初期治療時の肥満が乳癌再発率を増加させるか？																																																																											
<b>P</b>	HER2+乳癌初期治療後患者	<b>I</b>	初期治療時の肥満																																																																										
<b>C</b>	診断時に非肥満の患者	<b>O</b>	乳癌再発リスク																																																																										
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	10	<b>コード</b>	Sparano E1199 2012, Pajares 2013, Turkoz 2013, Crozier 2013, Mazarella																																																																								
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																																																										
<b>効果指標</b>	リスク比	<b>統合値</b>	1.16 ( 1.05 - 1.30 ) P= 0.006																																																																										
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr><td>Sparano E1199 2012</td><td>0.0583</td><td>0.131</td><td>17.6%</td><td>1.06 [0.82, 1.37]</td><td>2012</td></tr> <tr><td>Pajares 2013</td><td>0.1823</td><td>0.275</td><td>4.0%</td><td>1.20 [0.70, 2.06]</td><td>2013</td></tr> <tr><td>Turkoz 2013</td><td>0.4055</td><td>0.2069</td><td>7.1%</td><td>1.50 [1.00, 2.25]</td><td>2013</td></tr> <tr><td>Crozier 2013</td><td>0.2469</td><td>0.1011</td><td>29.6%</td><td>1.28 [1.05, 1.56]</td><td>2013</td></tr> <tr><td>Mazarella ER+HER2+ 2013</td><td>-0.2877</td><td>0.2838</td><td>3.8%</td><td>0.75 [0.43, 1.31]</td><td>2013</td></tr> <tr><td>Mazarella ER-HER2+ 2013</td><td>0.2927</td><td>0.2383</td><td>5.3%</td><td>1.34 [0.84, 2.14]</td><td>2013</td></tr> <tr><td>Widschwender 2015</td><td>1.1878</td><td>0.5392</td><td>1.0%</td><td>3.28 [1.14, 9.44]</td><td>2015</td></tr> <tr><td>Cecchini B-31 2016</td><td>0.0198</td><td>0.1052</td><td>27.4%</td><td>1.02 [0.83, 1.25]</td><td>2016</td></tr> <tr><td>Kawai 2016</td><td>0.2151</td><td>0.3065</td><td>3.2%</td><td>1.24 [0.68, 2.26]</td><td>2016</td></tr> <tr><td>Abubaker 2018</td><td>0.3436</td><td>0.5715</td><td>0.9%</td><td>1.41 [0.46, 4.32]</td><td>2018</td></tr> <tr><td><b>Total (95% CI)</b></td><td></td><td></td><td><b>100.0%</b></td><td><b>1.16 [1.05, 1.30]</b></td><td></td></tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 11.08, df = 9 (P = 0.27); I<sup>2</sup> = 19% Test for overall effect: Z = 2.76 (P = 0.006)</p>					Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year	Sparano E1199 2012	0.0583	0.131	17.6%	1.06 [0.82, 1.37]	2012	Pajares 2013	0.1823	0.275	4.0%	1.20 [0.70, 2.06]	2013	Turkoz 2013	0.4055	0.2069	7.1%	1.50 [1.00, 2.25]	2013	Crozier 2013	0.2469	0.1011	29.6%	1.28 [1.05, 1.56]	2013	Mazarella ER+HER2+ 2013	-0.2877	0.2838	3.8%	0.75 [0.43, 1.31]	2013	Mazarella ER-HER2+ 2013	0.2927	0.2383	5.3%	1.34 [0.84, 2.14]	2013	Widschwender 2015	1.1878	0.5392	1.0%	3.28 [1.14, 9.44]	2015	Cecchini B-31 2016	0.0198	0.1052	27.4%	1.02 [0.83, 1.25]	2016	Kawai 2016	0.2151	0.3065	3.2%	1.24 [0.68, 2.26]	2016	Abubaker 2018	0.3436	0.5715	0.9%	1.41 [0.46, 4.32]	2018	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.16 [1.05, 1.30]</b>	
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year																																																																							
Sparano E1199 2012	0.0583	0.131	17.6%	1.06 [0.82, 1.37]	2012																																																																								
Pajares 2013	0.1823	0.275	4.0%	1.20 [0.70, 2.06]	2013																																																																								
Turkoz 2013	0.4055	0.2069	7.1%	1.50 [1.00, 2.25]	2013																																																																								
Crozier 2013	0.2469	0.1011	29.6%	1.28 [1.05, 1.56]	2013																																																																								
Mazarella ER+HER2+ 2013	-0.2877	0.2838	3.8%	0.75 [0.43, 1.31]	2013																																																																								
Mazarella ER-HER2+ 2013	0.2927	0.2383	5.3%	1.34 [0.84, 2.14]	2013																																																																								
Widschwender 2015	1.1878	0.5392	1.0%	3.28 [1.14, 9.44]	2015																																																																								
Cecchini B-31 2016	0.0198	0.1052	27.4%	1.02 [0.83, 1.25]	2016																																																																								
Kawai 2016	0.2151	0.3065	3.2%	1.24 [0.68, 2.26]	2016																																																																								
Abubaker 2018	0.3436	0.5715	0.9%	1.41 [0.46, 4.32]	2018																																																																								
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.16 [1.05, 1.30]</b>																																																																									
	<p>コメント： 異質性は低く、効果は有意である。</p>																																																																												
<b>Funnel plot</b>	<p>コメント： 報告バイアスを示唆する分布は認められない。</p>																																																																												
	<p>その他の解析 施行せず。</p> <p>メタリグレーション</p> <p>感度分析</p> <p>コメント：</p>																																																																												

【4-9 メタアナリシス】

<b>CQ</b>		HER2+乳癌初期治療後患者において初期治療時の肥満が乳癌再発率を増加させるか？																																							
<b>P</b>	HER2+乳癌初期治療後患者	<b>I</b>	初期治療時の肥満																																						
<b>C</b>	診断時に非肥満の患者	<b>O</b>	乳癌死亡リスク																																						
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	4	<b>コード</b>	Sparano E1199 2012, Pajaras 2013, Jeon 2015, Kawai 2016																																				
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																						
<b>効果指標</b>	リスク比	<b>統合値</b>	1.15 ( 0.90 - 1.47 ) P= 0.28																																						
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>Sparano E1199 2012</td> <td>0</td> <td>0.1747</td> <td>51.7%</td> <td>1.00 [0.71, 1.41]</td> <td>2012</td> </tr> <tr> <td>Pajaras 2013</td> <td>0.4055</td> <td>0.3207</td> <td>15.3%</td> <td>1.50 [0.80, 2.81]</td> <td>2013</td> </tr> <tr> <td>Jeon 2015</td> <td>0.1484</td> <td>0.2577</td> <td>23.8%</td> <td>1.16 [0.70, 1.92]</td> <td>2015</td> </tr> <tr> <td>Kawai 2016</td> <td>0.4253</td> <td>0.4137</td> <td>9.2%</td> <td>1.53 [0.68, 3.44]</td> <td>2016</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.15 [0.90, 1.47]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 1.80, df = 3 (P = 0.61); I<sup>2</sup> = 0% Test for overall effect: Z = 1.09 (P = 0.28)</p>					Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year	Sparano E1199 2012	0	0.1747	51.7%	1.00 [0.71, 1.41]	2012	Pajaras 2013	0.4055	0.3207	15.3%	1.50 [0.80, 2.81]	2013	Jeon 2015	0.1484	0.2577	23.8%	1.16 [0.70, 1.92]	2015	Kawai 2016	0.4253	0.4137	9.2%	1.53 [0.68, 3.44]	2016	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.15 [0.90, 1.47]</b>	
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year																																			
Sparano E1199 2012	0	0.1747	51.7%	1.00 [0.71, 1.41]	2012																																				
Pajaras 2013	0.4055	0.3207	15.3%	1.50 [0.80, 2.81]	2013																																				
Jeon 2015	0.1484	0.2577	23.8%	1.16 [0.70, 1.92]	2015																																				
Kawai 2016	0.4253	0.4137	9.2%	1.53 [0.68, 3.44]	2016																																				
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.15 [0.90, 1.47]</b>																																					
<p>コメント: 異質性は低く、効果は有意ではない。</p>																																									
<b>Funnel plot</b>																																									
	<p>コメント: 報告バイアスを示唆する分布は認められない。</p>																																								
<b>その他の解析</b>	施行せず。			コメント:																																					
メタリグレーション																																									
感度分析																																									



【4-9 メタアナリシス】

<b>CQ</b>		HER2+乳癌初期治療後患者において初期治療時の肥満が乳癌再発率を増加させるか？																																																																					
<b>P</b>	HER2+乳癌初期治療後患者	<b>I</b>	初期治療時の肥満																																																																				
<b>C</b>	診断時に非肥満の患者	<b>O</b>	全死亡リスク																																																																				
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	9	<b>コード</b>	Sparano E1199 2012, Pajares 2013, Turkoz 2013, Jeon 2015, Crozier 2013,																																																																		
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																																																				
<b>効果指標</b>	リスク比	<b>統合値</b>	1.16 ( 1.02 - 1.31 ) P= 0.02																																																																				
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>Sparano E1199 2012</td> <td>-0.0101</td> <td>0.1554</td> <td>16.5%</td> <td>0.99 [0.73, 1.34]</td> <td>2012</td> </tr> <tr> <td>Mazzarella ER+HER2+ 2013</td> <td>0.0488</td> <td>0.3488</td> <td>3.3%</td> <td>1.05 [0.53, 2.08]</td> <td>2013</td> </tr> <tr> <td>Mazzarella ER-HER2+ 2013</td> <td>0.5822</td> <td>0.282</td> <td>5.0%</td> <td>1.79 [1.03, 3.11]</td> <td>2013</td> </tr> <tr> <td>Pajares 2013</td> <td>0.3365</td> <td>0.2855</td> <td>4.9%</td> <td>1.40 [0.80, 2.45]</td> <td>2013</td> </tr> <tr> <td>Turkoz 2013</td> <td>0.3365</td> <td>0.123</td> <td>26.4%</td> <td>1.40 [1.10, 1.78]</td> <td>2013</td> </tr> <tr> <td>Jeon 2015</td> <td>0.1655</td> <td>0.2047</td> <td>9.5%</td> <td>1.18 [0.79, 1.76]</td> <td>2015</td> </tr> <tr> <td>Widschwender 2015</td> <td>1.0225</td> <td>0.6684</td> <td>0.9%</td> <td>2.78 [0.75, 10.30]</td> <td>2015</td> </tr> <tr> <td>Cecchini B-31 2016</td> <td>-0.0619</td> <td>0.1152</td> <td>30.1%</td> <td>0.94 [0.75, 1.18]</td> <td>2016</td> </tr> <tr> <td>Abubaker 2018</td> <td>0.207</td> <td>0.3414</td> <td>3.4%</td> <td>1.23 [0.63, 2.40]</td> <td>2018</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.16 [1.02, 1.31]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 11.34, df = 8 (P = 0.18); I<sup>2</sup> = 29% Test for overall effect: Z = 2.34 (P = 0.02)</p>					Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year	Sparano E1199 2012	-0.0101	0.1554	16.5%	0.99 [0.73, 1.34]	2012	Mazzarella ER+HER2+ 2013	0.0488	0.3488	3.3%	1.05 [0.53, 2.08]	2013	Mazzarella ER-HER2+ 2013	0.5822	0.282	5.0%	1.79 [1.03, 3.11]	2013	Pajares 2013	0.3365	0.2855	4.9%	1.40 [0.80, 2.45]	2013	Turkoz 2013	0.3365	0.123	26.4%	1.40 [1.10, 1.78]	2013	Jeon 2015	0.1655	0.2047	9.5%	1.18 [0.79, 1.76]	2015	Widschwender 2015	1.0225	0.6684	0.9%	2.78 [0.75, 10.30]	2015	Cecchini B-31 2016	-0.0619	0.1152	30.1%	0.94 [0.75, 1.18]	2016	Abubaker 2018	0.207	0.3414	3.4%	1.23 [0.63, 2.40]	2018	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.16 [1.02, 1.31]</b>	
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year																																																																	
Sparano E1199 2012	-0.0101	0.1554	16.5%	0.99 [0.73, 1.34]	2012																																																																		
Mazzarella ER+HER2+ 2013	0.0488	0.3488	3.3%	1.05 [0.53, 2.08]	2013																																																																		
Mazzarella ER-HER2+ 2013	0.5822	0.282	5.0%	1.79 [1.03, 3.11]	2013																																																																		
Pajares 2013	0.3365	0.2855	4.9%	1.40 [0.80, 2.45]	2013																																																																		
Turkoz 2013	0.3365	0.123	26.4%	1.40 [1.10, 1.78]	2013																																																																		
Jeon 2015	0.1655	0.2047	9.5%	1.18 [0.79, 1.76]	2015																																																																		
Widschwender 2015	1.0225	0.6684	0.9%	2.78 [0.75, 10.30]	2015																																																																		
Cecchini B-31 2016	-0.0619	0.1152	30.1%	0.94 [0.75, 1.18]	2016																																																																		
Abubaker 2018	0.207	0.3414	3.4%	1.23 [0.63, 2.40]	2018																																																																		
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.16 [1.02, 1.31]</b>																																																																			
	<p>コメント: 異質性は中等度であり、効果は有意であった。</p>																																																																						
<b>Funnel plot</b>	<p>コメント: 報告バイアスを示唆する分布は認められない</p>																																																																						
	<p>コメント: 施行せず。</p>																																																																						
<b>その他の解析</b>	<p>メタリグレーション</p> <p>感度分析</p>				コメント:																																																																		

【4-9 メタアナリシス】

<b>CQ</b>		TNBC乳癌初期治療後患者において初期治療時の肥満が乳癌再発率を増加させるか？																																																																					
<b>P</b>	TNBC乳癌初期治療後患者	<b>I</b>	初期治療時の肥満																																																																				
<b>C</b>	診断時に非肥満の患者	<b>O</b>	乳癌再発リスク																																																																				
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	3	<b>コード</b>	Ademuyiwa 2011, Dawood 2012, Sparano E1199 2012, Moward 2013, Turkoz 2013, Tait 2014, Widschwendter 2015, Kawai 2016, Abubaker 2018																																																																		
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																																																				
<b>効果指標</b>	リスク比	<b>統合値</b>	1.06 ( 0.95 - 1.18 ) P= 0.29																																																																				
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>Ademuyiwa 2011</td> <td>-0.2107</td> <td>0.2564</td> <td>4.6%</td> <td>0.81 [0.49, 1.34]</td> <td>2011</td> </tr> <tr> <td>Dawood 2012</td> <td>0.0198</td> <td>0.0871</td> <td>39.9%</td> <td>1.02 [0.86, 1.21]</td> <td>2012</td> </tr> <tr> <td>Sparano E1199 2012</td> <td>0.0198</td> <td>0.124</td> <td>19.7%</td> <td>1.02 [0.80, 1.30]</td> <td>2012</td> </tr> <tr> <td>Moward 2013</td> <td>0.01</td> <td>0.2094</td> <td>6.9%</td> <td>1.01 [0.67, 1.52]</td> <td>2013</td> </tr> <tr> <td>Turkoz 2013</td> <td>0.3365</td> <td>0.1717</td> <td>10.3%</td> <td>1.40 [1.00, 1.96]</td> <td>2013</td> </tr> <tr> <td>Tait 2014</td> <td>-0.0408</td> <td>0.2314</td> <td>5.7%</td> <td>0.96 [0.61, 1.51]</td> <td>2014</td> </tr> <tr> <td>Widschwendter 2015</td> <td>1.1053</td> <td>0.357</td> <td>2.4%</td> <td>3.02 [1.50, 6.08]</td> <td>2015</td> </tr> <tr> <td>Kawai 2016</td> <td>0.0862</td> <td>0.1976</td> <td>7.8%</td> <td>1.09 [0.74, 1.61]</td> <td>2016</td> </tr> <tr> <td>Abubaker 2018</td> <td>-0.3425</td> <td>0.3325</td> <td>2.7%</td> <td>0.71 [0.37, 1.36]</td> <td>2018</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.06 [0.95, 1.18]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 14.33, df = 8 (P = 0.07); I<sup>2</sup> = 44% Test for overall effect: Z = 1.07 (P = 0.29)</p>					Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year	Ademuyiwa 2011	-0.2107	0.2564	4.6%	0.81 [0.49, 1.34]	2011	Dawood 2012	0.0198	0.0871	39.9%	1.02 [0.86, 1.21]	2012	Sparano E1199 2012	0.0198	0.124	19.7%	1.02 [0.80, 1.30]	2012	Moward 2013	0.01	0.2094	6.9%	1.01 [0.67, 1.52]	2013	Turkoz 2013	0.3365	0.1717	10.3%	1.40 [1.00, 1.96]	2013	Tait 2014	-0.0408	0.2314	5.7%	0.96 [0.61, 1.51]	2014	Widschwendter 2015	1.1053	0.357	2.4%	3.02 [1.50, 6.08]	2015	Kawai 2016	0.0862	0.1976	7.8%	1.09 [0.74, 1.61]	2016	Abubaker 2018	-0.3425	0.3325	2.7%	0.71 [0.37, 1.36]	2018	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.06 [0.95, 1.18]</b>	
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year																																																																	
Ademuyiwa 2011	-0.2107	0.2564	4.6%	0.81 [0.49, 1.34]	2011																																																																		
Dawood 2012	0.0198	0.0871	39.9%	1.02 [0.86, 1.21]	2012																																																																		
Sparano E1199 2012	0.0198	0.124	19.7%	1.02 [0.80, 1.30]	2012																																																																		
Moward 2013	0.01	0.2094	6.9%	1.01 [0.67, 1.52]	2013																																																																		
Turkoz 2013	0.3365	0.1717	10.3%	1.40 [1.00, 1.96]	2013																																																																		
Tait 2014	-0.0408	0.2314	5.7%	0.96 [0.61, 1.51]	2014																																																																		
Widschwendter 2015	1.1053	0.357	2.4%	3.02 [1.50, 6.08]	2015																																																																		
Kawai 2016	0.0862	0.1976	7.8%	1.09 [0.74, 1.61]	2016																																																																		
Abubaker 2018	-0.3425	0.3325	2.7%	0.71 [0.37, 1.36]	2018																																																																		
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.06 [0.95, 1.18]</b>																																																																			
	<p>コメント: 異質性は中等度であり、効果は有意ではない。</p>																																																																						
<b>Funnel plot</b>	<p>コメント: 報告バイアスを示唆する分布は認められない。</p>																																																																						
	<p>コメント: 施行せず。</p>																																																																						
<b>その他の解析</b>	<p>メタリグレッション</p> <p>感度分析</p>				<p>コメント:</p>																																																																		

【4-9 メタアナリシス】

<b>CQ</b>		TNBC乳癌初期治療後患者において初期治療時の肥満が乳癌再発率を増加させるか？																																													
<b>P</b>	TNBC乳癌初期治療後患者	<b>I</b>	初期治療時の肥満																																												
<b>C</b>	診断時に非肥満の患者	<b>O</b>	乳癌死亡リスク																																												
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	3	<b>コード</b>	Sparano E1199 2012, Sun 2015, Jeon 2015, Kawai 2016, Bao 2016																																										
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																												
<b>効果指標</b>	リスク比	<b>統合値</b>	1.20 ( 0.99 - 1.46 ) P= 0.07																																												
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>Sparano E1199 2012</td> <td>0</td> <td>0.1747</td> <td>32.2%</td> <td>1.00 [0.71, 1.41]</td> <td>2012</td> </tr> <tr> <td>Sun 2015</td> <td>0.892</td> <td>0.4707</td> <td>4.4%</td> <td>2.44 [0.97, 6.14]</td> <td>2015</td> </tr> <tr> <td>Jeon 2015</td> <td>0.1484</td> <td>0.1647</td> <td>36.3%</td> <td>1.16 [0.84, 1.60]</td> <td>2015</td> </tr> <tr> <td>Kawai 2016</td> <td>0.1044</td> <td>0.2576</td> <td>14.8%</td> <td>1.11 [0.67, 1.84]</td> <td>2016</td> </tr> <tr> <td>Bao 2016</td> <td>0.6043</td> <td>0.2834</td> <td>12.2%</td> <td>1.83 [1.05, 3.19]</td> <td>2016</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.20 [0.99, 1.46]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 5.71, df = 4 (P = 0.22); I<sup>2</sup> = 30% Test for overall effect: Z = 1.84 (P = 0.07)</p>				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year	Sparano E1199 2012	0	0.1747	32.2%	1.00 [0.71, 1.41]	2012	Sun 2015	0.892	0.4707	4.4%	2.44 [0.97, 6.14]	2015	Jeon 2015	0.1484	0.1647	36.3%	1.16 [0.84, 1.60]	2015	Kawai 2016	0.1044	0.2576	14.8%	1.11 [0.67, 1.84]	2016	Bao 2016	0.6043	0.2834	12.2%	1.83 [1.05, 3.19]	2016	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.20 [0.99, 1.46]</b>		
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year																																									
Sparano E1199 2012	0	0.1747	32.2%	1.00 [0.71, 1.41]	2012																																										
Sun 2015	0.892	0.4707	4.4%	2.44 [0.97, 6.14]	2015																																										
Jeon 2015	0.1484	0.1647	36.3%	1.16 [0.84, 1.60]	2015																																										
Kawai 2016	0.1044	0.2576	14.8%	1.11 [0.67, 1.84]	2016																																										
Bao 2016	0.6043	0.2834	12.2%	1.83 [1.05, 3.19]	2016																																										
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.20 [0.99, 1.46]</b>																																											
コメント: 異質性があり、傾向はあるが効果は有意でない。																																															
<b>Funnel plot</b>																																															
	コメント: 報告バイアスを示唆する分布は認められない。																																														
<b>その他の解析</b>	施行せず。				コメント:																																										
メタリグレーション																																															
感度分析																																															

【4-9 メタアナリシス】

<b>CQ</b>		TNBC乳癌初期治療後患者において初期治療時の肥満が全死亡率を増加させるか？																																																																																																
<b>P</b>	TNBC乳癌初期治療後患者	<b>I</b>	初期治療時の肥満																																																																																															
<b>C</b>	診断時に非肥満の患者	<b>O</b>	全死亡リスク																																																																																															
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	4	<b>コード</b>	Bao PP 2016,Dawood S 2012,Mowad R 2013,Widschwendter P 2015																																																																																													
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																																																																															
<b>効果指標</b>	リスク比	<b>統合値</b>	1.26 ( 1.02 - 1.56 ) P= 0.03																																																																																															
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th rowspan="2">log[Hazard Ratio]</th> <th rowspan="2">SE</th> <th rowspan="2">Weight</th> <th colspan="2">Hazard Ratio</th> <th rowspan="2">Year</th> </tr> <tr> <th>IV, Random, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>Ademuyiwa 2011</td> <td>-0.0619</td> <td>0.2828</td> <td>7.8%</td> <td>0.94</td> <td>[0.54, 1.64]</td> <td>2011</td> </tr> <tr> <td>Dawood 2012</td> <td>-0.0305</td> <td>0.092</td> <td>14.9%</td> <td>0.97</td> <td>[0.81, 1.16]</td> <td>2012</td> </tr> <tr> <td>Sparano E1199 2012</td> <td>0.1044</td> <td>0.1362</td> <td>13.2%</td> <td>1.11</td> <td>[0.85, 1.45]</td> <td>2012</td> </tr> <tr> <td>Turkoz 2013</td> <td>0.5306</td> <td>0.2221</td> <td>9.8%</td> <td>1.70</td> <td>[1.10, 2.63]</td> <td>2013</td> </tr> <tr> <td>Moward 2013</td> <td>0.3075</td> <td>0.2902</td> <td>7.6%</td> <td>1.36</td> <td>[0.77, 2.40]</td> <td>2013</td> </tr> <tr> <td>Tait 2014</td> <td>-0.1393</td> <td>0.2433</td> <td>9.1%</td> <td>0.87</td> <td>[0.54, 1.40]</td> <td>2014</td> </tr> <tr> <td>Widschwendter 2015</td> <td>1.3481</td> <td>0.4201</td> <td>4.8%</td> <td>3.85</td> <td>[1.69, 8.77]</td> <td>2015</td> </tr> <tr> <td>Jeon 2015</td> <td>0.1655</td> <td>0.2047</td> <td>10.5%</td> <td>1.18</td> <td>[0.79, 1.76]</td> <td>2015</td> </tr> <tr> <td>Sun 2015</td> <td>1.0043</td> <td>0.3865</td> <td>5.4%</td> <td>2.73</td> <td>[1.28, 5.82]</td> <td>2015</td> </tr> <tr> <td>Bao 2016</td> <td>0.5822</td> <td>0.2673</td> <td>8.3%</td> <td>1.79</td> <td>[1.06, 3.02]</td> <td>2016</td> </tr> <tr> <td>Abubaker 2018</td> <td>-0.2231</td> <td>0.2606</td> <td>8.5%</td> <td>0.80</td> <td>[0.48, 1.33]</td> <td>2018</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.26</b></td> <td><b>[1.02, 1.56]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Tau<sup>2</sup> = 0.07; Chi<sup>2</sup> = 26.63, df = 10 (P = 0.003); I<sup>2</sup> = 62%  Test for overall effect: Z = 2.14 (P = 0.03)</p>				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio		Year	IV, Random, 95% CI	Year	Ademuyiwa 2011	-0.0619	0.2828	7.8%	0.94	[0.54, 1.64]	2011	Dawood 2012	-0.0305	0.092	14.9%	0.97	[0.81, 1.16]	2012	Sparano E1199 2012	0.1044	0.1362	13.2%	1.11	[0.85, 1.45]	2012	Turkoz 2013	0.5306	0.2221	9.8%	1.70	[1.10, 2.63]	2013	Moward 2013	0.3075	0.2902	7.6%	1.36	[0.77, 2.40]	2013	Tait 2014	-0.1393	0.2433	9.1%	0.87	[0.54, 1.40]	2014	Widschwendter 2015	1.3481	0.4201	4.8%	3.85	[1.69, 8.77]	2015	Jeon 2015	0.1655	0.2047	10.5%	1.18	[0.79, 1.76]	2015	Sun 2015	1.0043	0.3865	5.4%	2.73	[1.28, 5.82]	2015	Bao 2016	0.5822	0.2673	8.3%	1.79	[1.06, 3.02]	2016	Abubaker 2018	-0.2231	0.2606	8.5%	0.80	[0.48, 1.33]	2018	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.26</b>	<b>[1.02, 1.56]</b>		<p>コメント： 異質性は高いが、有意な効果である。</p>
Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio					Year																																																																																									
				IV, Random, 95% CI	Year																																																																																													
Ademuyiwa 2011	-0.0619	0.2828	7.8%	0.94	[0.54, 1.64]	2011																																																																																												
Dawood 2012	-0.0305	0.092	14.9%	0.97	[0.81, 1.16]	2012																																																																																												
Sparano E1199 2012	0.1044	0.1362	13.2%	1.11	[0.85, 1.45]	2012																																																																																												
Turkoz 2013	0.5306	0.2221	9.8%	1.70	[1.10, 2.63]	2013																																																																																												
Moward 2013	0.3075	0.2902	7.6%	1.36	[0.77, 2.40]	2013																																																																																												
Tait 2014	-0.1393	0.2433	9.1%	0.87	[0.54, 1.40]	2014																																																																																												
Widschwendter 2015	1.3481	0.4201	4.8%	3.85	[1.69, 8.77]	2015																																																																																												
Jeon 2015	0.1655	0.2047	10.5%	1.18	[0.79, 1.76]	2015																																																																																												
Sun 2015	1.0043	0.3865	5.4%	2.73	[1.28, 5.82]	2015																																																																																												
Bao 2016	0.5822	0.2673	8.3%	1.79	[1.06, 3.02]	2016																																																																																												
Abubaker 2018	-0.2231	0.2606	8.5%	0.80	[0.48, 1.33]	2018																																																																																												
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.26</b>	<b>[1.02, 1.56]</b>																																																																																													
<b>Funnel plot</b>					<p>コメント： 報告バイアスを示唆する分布を認める。</p>																																																																																													
<b>その他の解析</b>	施行せず。			コメント：																																																																																														
メタリグレーション																																																																																																		
感度分析																																																																																																		

【4-9 メタアナリシス】

<b>CQ</b>	乳癌初期治療後患者において初期治療後の肥満が初期治療後に体重を維持した患者と比べて乳癌再発率を増加させるか？																																																			
<b>P</b>	乳癌初期治療後患者	<b>I</b>	初期治療後の肥満																																																	
<b>C</b>	初期治療後に体重を維持した患者	<b>O</b>	乳癌再発リスク																																																	
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	5	<b>コード</b> Kroenke 2005, Jeon 2014, Fedele 2014, Nechuta 2016, Raghavendra 2017, Jung 2020																																																
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																																	
<b>効果指標</b>	リスク比	<b>統合値</b>	1.29 ( 1.11 - 1.50 ) P= 0.001																																																	
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>Kroenke 2005</td> <td>0.4253</td> <td>0.197</td> <td>15.7%</td> <td>1.53 [1.04, 2.25]</td> <td>2005</td> </tr> <tr> <td>Jeon 2014</td> <td>0.8755</td> <td>0.5605</td> <td>1.9%</td> <td>2.40 [0.80, 7.20]</td> <td>2014</td> </tr> <tr> <td>Fedele 2014</td> <td>0.5306</td> <td>0.2512</td> <td>9.7%</td> <td>1.70 [1.04, 2.78]</td> <td>2014</td> </tr> <tr> <td>Nechuta 2016</td> <td>0.2151</td> <td>0.1098</td> <td>50.5%</td> <td>1.24 [1.00, 1.54]</td> <td>2016</td> </tr> <tr> <td>Raghavendra 2017</td> <td>-0.0513</td> <td>0.2177</td> <td>12.8%</td> <td>0.95 [0.62, 1.46]</td> <td>2017</td> </tr> <tr> <td>Jung 2020</td> <td>0.1989</td> <td>0.2551</td> <td>9.4%</td> <td>1.22 [0.74, 2.01]</td> <td>2020</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.29 [1.11, 1.50]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 5.34, df = 5 (P = 0.38); I<sup>2</sup> = 6%            Test for overall effect: Z = 3.28 (P = 0.001)</p>				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year	Kroenke 2005	0.4253	0.197	15.7%	1.53 [1.04, 2.25]	2005	Jeon 2014	0.8755	0.5605	1.9%	2.40 [0.80, 7.20]	2014	Fedele 2014	0.5306	0.2512	9.7%	1.70 [1.04, 2.78]	2014	Nechuta 2016	0.2151	0.1098	50.5%	1.24 [1.00, 1.54]	2016	Raghavendra 2017	-0.0513	0.2177	12.8%	0.95 [0.62, 1.46]	2017	Jung 2020	0.1989	0.2551	9.4%	1.22 [0.74, 2.01]	2020	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.29 [1.11, 1.50]</b>	
Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year																																															
Kroenke 2005	0.4253	0.197	15.7%	1.53 [1.04, 2.25]	2005																																															
Jeon 2014	0.8755	0.5605	1.9%	2.40 [0.80, 7.20]	2014																																															
Fedele 2014	0.5306	0.2512	9.7%	1.70 [1.04, 2.78]	2014																																															
Nechuta 2016	0.2151	0.1098	50.5%	1.24 [1.00, 1.54]	2016																																															
Raghavendra 2017	-0.0513	0.2177	12.8%	0.95 [0.62, 1.46]	2017																																															
Jung 2020	0.1989	0.2551	9.4%	1.22 [0.74, 2.01]	2020																																															
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.29 [1.11, 1.50]</b>																																																
	コメント: 異質性は低く、効果も有意である。																																																			
<b>Funnel plot</b>																																																				
	コメント: 報告バイアスを示唆する分布を認める。																																																			
<b>その他の解析</b>	施行せず。			コメント:																																																
メタリグレーション																																																				
感度分析																																																				

【4-9 メタアナリシス】

<b>CQ</b>		乳癌初期治療後患者において初期治療後の肥満が初期治療後に体重を維持した患者と比べて乳癌死亡率を増加させるか？																																																																					
<b>P</b>	乳癌初期治療後患者	<b>I</b>	初期治療後の肥満																																																																				
<b>C</b>	初期治療後に体重を維持した患者	<b>O</b>	乳癌死亡リスク																																																																				
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	4	<b>コード</b>	Kroenke 2005, Nichols 2009, Chen 2010, Caan(USA) 2012, Bradshaw 2012, Caan(Shanghai)2012, Bao 2016, Cespedes 2017, Jung 2020																																																																		
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																																																				
<b>効果指標</b>	リスク比	<b>統合値</b>	1.24 ( 1.09 - 1.41 ) P= 0.0009																																																																				
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr><td>Kroenke 2005</td><td>0.4947</td><td>0.2179</td><td>9.0%</td><td>1.64 [1.07, 2.51]</td><td>2005</td></tr> <tr><td>Nichols 2009</td><td>0.5766</td><td>0.2891</td><td>5.1%</td><td>1.78 [1.01, 3.14]</td><td>2009</td></tr> <tr><td>Chen 2010</td><td>0.2624</td><td>0.1991</td><td>10.7%</td><td>1.30 [0.88, 1.92]</td><td>2010</td></tr> <tr><td>Caan (USA) 2012</td><td>0.0296</td><td>0.104</td><td>39.3%</td><td>1.03 [0.84, 1.26]</td><td>2012</td></tr> <tr><td>Bradshaw 2012</td><td>1.0438</td><td>0.4613</td><td>2.0%</td><td>2.84 [1.15, 7.01]</td><td>2012</td></tr> <tr><td>Caan(Shanghai) 2012</td><td>0.2231</td><td>0.1791</td><td>13.3%</td><td>1.25 [0.88, 1.78]</td><td>2012</td></tr> <tr><td>Bao 2016</td><td>0.3365</td><td>0.305</td><td>4.6%</td><td>1.40 [0.77, 2.55]</td><td>2016</td></tr> <tr><td>Cespedes 2017</td><td>-0.0202</td><td>0.194</td><td>11.3%</td><td>0.98 [0.67, 1.43]</td><td>2017</td></tr> <tr><td>Jung 2020</td><td>0.8065</td><td>0.2976</td><td>4.8%</td><td>2.24 [1.25, 4.01]</td><td>2020</td></tr> <tr><td><b>Total (95% CI)</b></td><td></td><td></td><td><b>100.0%</b></td><td><b>1.24 [1.09, 1.41]</b></td><td></td></tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 15.26, df = 8 (P = 0.05); I<sup>2</sup> = 48% Test for overall effect: Z = 3.31 (P = 0.0009)</p> <p>コメント: 異質性は中等度であり、結果は有意である。</p>					Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year	Kroenke 2005	0.4947	0.2179	9.0%	1.64 [1.07, 2.51]	2005	Nichols 2009	0.5766	0.2891	5.1%	1.78 [1.01, 3.14]	2009	Chen 2010	0.2624	0.1991	10.7%	1.30 [0.88, 1.92]	2010	Caan (USA) 2012	0.0296	0.104	39.3%	1.03 [0.84, 1.26]	2012	Bradshaw 2012	1.0438	0.4613	2.0%	2.84 [1.15, 7.01]	2012	Caan(Shanghai) 2012	0.2231	0.1791	13.3%	1.25 [0.88, 1.78]	2012	Bao 2016	0.3365	0.305	4.6%	1.40 [0.77, 2.55]	2016	Cespedes 2017	-0.0202	0.194	11.3%	0.98 [0.67, 1.43]	2017	Jung 2020	0.8065	0.2976	4.8%	2.24 [1.25, 4.01]	2020	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.24 [1.09, 1.41]</b>	
Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Year																																																																		
Kroenke 2005	0.4947	0.2179	9.0%	1.64 [1.07, 2.51]	2005																																																																		
Nichols 2009	0.5766	0.2891	5.1%	1.78 [1.01, 3.14]	2009																																																																		
Chen 2010	0.2624	0.1991	10.7%	1.30 [0.88, 1.92]	2010																																																																		
Caan (USA) 2012	0.0296	0.104	39.3%	1.03 [0.84, 1.26]	2012																																																																		
Bradshaw 2012	1.0438	0.4613	2.0%	2.84 [1.15, 7.01]	2012																																																																		
Caan(Shanghai) 2012	0.2231	0.1791	13.3%	1.25 [0.88, 1.78]	2012																																																																		
Bao 2016	0.3365	0.305	4.6%	1.40 [0.77, 2.55]	2016																																																																		
Cespedes 2017	-0.0202	0.194	11.3%	0.98 [0.67, 1.43]	2017																																																																		
Jung 2020	0.8065	0.2976	4.8%	2.24 [1.25, 4.01]	2020																																																																		
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.24 [1.09, 1.41]</b>																																																																			
<b>Funnel plot</b>	<p>コメント: 報告バイアスを示唆する分布を認める。</p>																																																																						
<b>その他の解析</b>	施行せず。			コメント:																																																																			
メタリグレッション																																																																							
感度分析																																																																							

【4-9 メタアナリシス】

<b>CQ</b>		乳癌初期治療後患者において初期治療後の肥満が初期治療後に体重を維持した患者と比べて全死亡率を増加させるか？																																																																				
<b>P</b>	乳癌初期治療後患者	<b>I</b>	初期治療後の肥満																																																																			
<b>C</b>	初期治療後に体重を維持した患者	<b>O</b>	全死亡リスク																																																																			
<b>研究デザイン</b>	コホート研究	<b>文献数</b>	7	<b>コード</b> Kroenke 2005, Nichols 2009, Chen 2010, Bradshaw 2012, Caan(Shanghai) 2012, Caan(USA) 2012, Bao 2016, Cespedes 2017, Jung 2020																																																																		
<b>モデル</b>	コホート研究	<b>方法</b>	Inverse-variance method (RevMan5.3)																																																																			
<b>効果指標</b>	リスク比	<b>統合値</b>	1.36 ( 1.15 - 1.61 ) P= 0.0003																																																																			
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Random, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>Kroenke 2005</td> <td>0.4637</td> <td>0.1788</td> <td>11.7%</td> <td>1.59 [1.12, 2.26]</td> <td>2005</td> </tr> <tr> <td>Nichols 2009</td> <td>0.5306</td> <td>0.1735</td> <td>12.0%</td> <td>1.70 [1.21, 2.39]</td> <td>2009</td> </tr> <tr> <td>Chen 2010</td> <td>0.4318</td> <td>0.2052</td> <td>10.0%</td> <td>1.54 [1.03, 2.30]</td> <td>2010</td> </tr> <tr> <td>Bradshaw 2012</td> <td>0.9821</td> <td>0.3404</td> <td>4.9%</td> <td>2.67 [1.37, 5.20]</td> <td>2012</td> </tr> <tr> <td>Caan(Shanghai) 2012</td> <td>0.1484</td> <td>0.1647</td> <td>12.7%</td> <td>1.16 [0.84, 1.60]</td> <td>2012</td> </tr> <tr> <td>Caan (USA) 2012</td> <td>0.1398</td> <td>0.0816</td> <td>19.9%</td> <td>1.15 [0.98, 1.35]</td> <td>2012</td> </tr> <tr> <td>Bao 2016</td> <td>0.2469</td> <td>0.2865</td> <td>6.4%</td> <td>1.28 [0.73, 2.24]</td> <td>2016</td> </tr> <tr> <td>Cespedes 2017</td> <td>-0.0202</td> <td>0.1433</td> <td>14.3%</td> <td>0.98 [0.74, 1.30]</td> <td>2017</td> </tr> <tr> <td>Jung 2020</td> <td>0.4947</td> <td>0.2423</td> <td>8.1%</td> <td>1.64 [1.02, 2.64]</td> <td>2020</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>1.36 [1.15, 1.61]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Tau<sup>2</sup> = 0.03; Chi<sup>2</sup> = 16.21, df = 8 (P = 0.04); I<sup>2</sup> = 51%  Test for overall effect: Z = 3.66 (P = 0.0003)</p>				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI	Year	Kroenke 2005	0.4637	0.1788	11.7%	1.59 [1.12, 2.26]	2005	Nichols 2009	0.5306	0.1735	12.0%	1.70 [1.21, 2.39]	2009	Chen 2010	0.4318	0.2052	10.0%	1.54 [1.03, 2.30]	2010	Bradshaw 2012	0.9821	0.3404	4.9%	2.67 [1.37, 5.20]	2012	Caan(Shanghai) 2012	0.1484	0.1647	12.7%	1.16 [0.84, 1.60]	2012	Caan (USA) 2012	0.1398	0.0816	19.9%	1.15 [0.98, 1.35]	2012	Bao 2016	0.2469	0.2865	6.4%	1.28 [0.73, 2.24]	2016	Cespedes 2017	-0.0202	0.1433	14.3%	0.98 [0.74, 1.30]	2017	Jung 2020	0.4947	0.2423	8.1%	1.64 [1.02, 2.64]	2020	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.36 [1.15, 1.61]</b>	
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI	Year																																																																
Kroenke 2005	0.4637	0.1788	11.7%	1.59 [1.12, 2.26]	2005																																																																	
Nichols 2009	0.5306	0.1735	12.0%	1.70 [1.21, 2.39]	2009																																																																	
Chen 2010	0.4318	0.2052	10.0%	1.54 [1.03, 2.30]	2010																																																																	
Bradshaw 2012	0.9821	0.3404	4.9%	2.67 [1.37, 5.20]	2012																																																																	
Caan(Shanghai) 2012	0.1484	0.1647	12.7%	1.16 [0.84, 1.60]	2012																																																																	
Caan (USA) 2012	0.1398	0.0816	19.9%	1.15 [0.98, 1.35]	2012																																																																	
Bao 2016	0.2469	0.2865	6.4%	1.28 [0.73, 2.24]	2016																																																																	
Cespedes 2017	-0.0202	0.1433	14.3%	0.98 [0.74, 1.30]	2017																																																																	
Jung 2020	0.4947	0.2423	8.1%	1.64 [1.02, 2.64]	2020																																																																	
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>1.36 [1.15, 1.61]</b>																																																																		
<p>コメント： 異質性が高く、結果は有意である。</p>																																																																						
<b>Funnel plot</b>																																																																						
	<p>コメント： 報告バイアスを示唆する分布を認めない。</p>																																																																					
<b>その他の解析</b>	施行せず。			コメント：																																																																		
メタリグレーション																																																																						
感度分析																																																																						